硼替佐米耐药多发性骨髓瘤细胞株KM3/BTZ的建立

山东大学学报(医学版) ›› 2013, Vol. 51 ›› Issue (2): 33-.

硼替佐米耐药多发性骨髓瘤细胞株KM3/BTZ的建立

蒲业迪，李丽珍，马道新，董珂，赵川莉，宋强，王鲁群

山东大学齐鲁医院血液科，济南 250012

收稿日期:2012-11-06 出版日期:2013-02-10 发布日期:2013-02-10
通讯作者: 王鲁群（1964- ），男，教授，主要从事淋巴瘤和多发性骨髓瘤的研究。E-mail:Wanglq@sdu.edu.cn
作者简介:蒲业迪（1987- ），女，硕士研究生，主要从事多发性骨髓瘤的研究。E-mail:didiis1987@163.com
基金资助:
山东省科技攻关课题基金（2008GG10002049）

Establishment of a bortezomib-resistant cell line KM3/BTZ of human multiple myeloma

PU Ye-di, LI Li-zhen, MA Dao-xin, DONG Ke,ZHAO Chuan-li, SONG Qiang, WANG Lu-qun

Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, China

Received:2012-11-06 Online:2013-02-10 Published:2013-02-10

摘要/Abstract

摘要：

目的建立人多发性骨髓瘤耐硼替佐米的细胞株，并对其生物学特性及耐药机制进行初步探讨。方法采用浓度梯度递增法，以人多发性骨髓瘤KM3细胞株为亲本，建立耐硼替佐米的多发性骨髓瘤细胞株，绘制生长曲线，并计算倍增时间；MTT法鉴定耐药细胞株的耐药性；RT-PCR方法检测MDR-1在亲代和耐药细胞株中的表达情况。结果成功建立耐硼替佐米的多发性骨髓瘤细胞株KM3/BTZ，耐药倍数为19.7倍。与亲代细胞相比，耐药细胞株倍增时间延长（P＜0.05）。多药耐药相关基因MDR-1未参与耐药性的发生。结论成功建立人多发性骨髓瘤耐药细胞株KM3/BTZ，耐药性稳定，为研究耐药机制及逆转耐药提供了理想的模型。

关键词: 硼替佐米；耐药；多发性骨髓瘤；细胞株

Abstract:

Objective To establish a bortezomib-resistant cell line KM3/BTZ of human multiple myeloma (MM) and investigate its biological characteristics and mechanisms of drug-resistant in MM preliminarily. Methods The KM3 cell line was exposured to bortezomib at increasing doses to obtain a stable bortezomib-resistant KM3/BTZ in vitro. The growth curve was drawn and the doubling time was counted. MTT assay was used to evaluate the sensitivity of drug resistance. The expression of MDR-1 mRNA was determined by RT-PCR in KM3 and KM3/BTZ cell lines. Results The KM3/BTZ cell line resistant to bortezomib was established successfully with the resistance index of 19.7 (KM3/BTZ to KM3). Compared with the parent cells, KM3/BTZ exhibited a significant longer doubling time (P＜0.05) .The expression of MDR-1 mRNA was not observed in either resistant or parent cells. Conclusion We have successfully established bortezomib resistance cell line KM3/BTZ and its drug-resistant character is stable. The KM3/BTZ cell line might serve as an ideal model to explore the drug-resistance mechanisms and to reverse the drug resistance.

Key words: Bortezomib; Drug resistance; Multiple myeloma; Cell line

中图分类号:

R733.3

蒲业迪，李丽珍，马道新，董珂，赵川莉，宋强，王鲁群. 硼替佐米耐药多发性骨髓瘤细胞株KM3/BTZ的建立[J]. 山东大学学报(医学版), 2013, 51(2): 33-.

PU Ye-di, LI Li-zhen, MA Dao-xin, DONG Ke,ZHAO Chuan-li, SONG Qiang, WANG Lu-qun. Establishment of a bortezomib-resistant cell line KM3/BTZ of human multiple myeloma[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(2): 33-.

参考文献

相关文章 5

[1]	李银柱1，徐文君2，崔景英2，任翠爱2 . 53例二磷酸盐相关颌骨坏死诊治的回顾性分析[J]. 山东大学学报(医学版), 2013, 51(1): 109-112.
[2]	张晶晶，马道新，孔海丽，王慧君，孙元欣，刘传方. 靶向AML1/ETO的siRNA增强Kasumi-1细胞对组蛋白去乙酰化酶抑制剂的敏感性[J]. 山东大学学报(医学版), 2011, 49(7): 68-73.
[3]	赵婷,宋强，李丽珍，王鲁群，赵川莉. 骨髓增生异常综合征患者EPO水平的测定及其受体的表达[J]. 山东大学学报(医学版), 2011, 49(1): 67-70.
[4]	卢菲, 刘传方，马道新，刘彦平，孔海丽，张晶晶. 5-氮-2′-脱氧胞苷对RPMI8226细胞增殖、凋亡及SOCS-1基因表达的影响[J]. 山东大学学报(医学版), 2010, 48(4): 45-.
[5]	李珊，李丽珍，宋强，赵川莉，闫树昕，王鲁群. 和厚朴酚联合硼替佐米对骨髓瘤KM3细胞增殖和凋亡的作用[J]. 山东大学学报(医学版), 2010, 48(12): 32-36.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed